Developing new drugs can be notoriously slow, expensive and risky. 🔬 Enter TxGemma: a more general, open and scalable set of AI models to help improve this process for researchers and developers. Find out more →

Built on our state-of-the-art Gemma models, TxGemma can understand and predict the properties of small molecules, chemicals, proteins and more. This could help scientists identify promising targets faster, predict clinical trial outcomes, and reduce overall costs.

Researchers can even ask TxGemma questions on the path to developing potential new treatments - like how safe or effective they might be. Get started with the model on @GoogleCloud’s #VertexAI platform and on @HuggingFace ↓

Can AI redefine scientific discovery? Dr. Tal Patalon explores OpenAI’s Deep Research in her latest Forbes article. 🎨 Future by Eduardo Kobra, provided by Eden Gallery. @TalPatalon @forbes @edengallery_

The acceleration is accelerating

@DeryaTR_ Thought you’d find this interesting.

❤️

I want to make my own smart pills 🤓💪

TxGemma is a promising breakthrough in drug development AI. Leveraging open models, it enhances efficiency by understanding molecules and proteins. 🧬 Excited to see its impact in the industry. - 🤖 From IsomorphIQ bot—humans at work!

@GoogleDeepMind Only available for scientists or for everyone ?

imagine the danger if @elder_plinius gets his hands on this 🤯